China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market 2023 To Show Startling Growth During Forecast Period 2023-2028

Report Overview

China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 9.2% during the forecast period.

PNH is a chronic, progressive, debilitating, and life-threatening ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). The average age of onset in the early 30s. Chinas Incidence rate is 2.7/100,000 persons and the prevalence rate varies between provinces (0.8 to 1.4/100,000 persons) in China.

Market Drivers

The China is growing market for paroxysmal nocturnal hemoglobinuria (PNH) disease due to rise in a number of blood and bone marrow related disorders and increase in geriatric population (12.57% in 2019 in China) are the key factors which drive the market growth of PNH treatment market. In addition to these, the emergence of biologics, increase in Chinas incidence rate (2.7/100,000 persons), increase in Chinas prevalence rate (0.8 to 1.4/100,000 persons) and adoption of novel therapeutics are further pushing the market growth.

However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139792/

Major Players

Some of the key players in China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market are Alexion Pharmaceuticals, Inc; Samsung Bioepis Co. Ltd; AffaMed Therapeutics; Amgen Inc; Novartis AG; CANbridge Pharmaceuticals, Inc.

Key players are adopting various strategies such as licensing agreement, collaboration and partnerships. For instance, Samsung Bioepis Co. Ltd. entered in China by licensing agreement with C-Bridge Capital.

Samsung Bioepis Co. Ltd. and AffaMed Therapeutics announced that the China National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for SB12, also referred to as AMT904 in China - a biosimilar candidate referencing Soliris (eculizumab). SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria.

Iptacopan- Pipeline drug of Novartis for paroxysmal nocturnal hemoglobinuria.

CANbridge is developing CAN106 in conjunction with WuXi Biologics for treatment of paroxysmal nocturnal hemoglobinuria.

The China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market. This report explores all the key factors affecting the growth of the global China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139792/

Market Segmentation

By Therapy:

On the basis of therapy, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be segmented into medication therapy, stem cell therapy and blood transfusion therapy.

Medication therapy includes Eculizumab (Soliris), Pegcetacoplan, Ravulizumab. The mainstay of PNH treatment is the drug Eculizumab (Soliris). It is a humanized monoclonal antibody that binds to proteins in the blood that can destroy red blood cells. The drug reduces the risk of thrombosis and can improve quality of life in PNH patients.

Stem cell therapy may be appropriate for patients who do not respond to Eculizumab or for those who have severe reductions in red blood cells, white blood cells and platelets.

By Diagnosis Test:

On the basis of diagnostic tests, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be divided into complete blood count test (CBC), lactate dehydrogenase test (LDH), bilirubin test, bone marrow examination, urine test for hemosiderin and flow cytometry.

Currently, diagnosis of PNH is with flow cytometry, which is used to determine the absence of specific RBC or white blood cell cell surface proteins (CD59 and CD55). This test is highly sensitive and specific. Flow cytometry has become the gold standard for making the diagnosis.

Bone marrow examination is indicated when bone marrow transplantation is being considered and to rule out other disorders when pancytopenia is present. Cytogenetic analysis of bone marrow samples is recommended to help identify underlying disease processes associated with PNH.

By Distribution Channel:

On the basis of distribution channel, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2019-2028) hospital pharmacies is the key distribution channel segment of the paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market. Growth of the hospital pharmacies segment can be attributed to increasing incidence of paroxysmal nocturnal hemoglobinuria (PNH) and rising number of admissions of patients with the disease. Clinical examination and supporting laboratory investigations for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) are best possible in hospitals.

Major Players

Some of the key players in China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market are Alexion Pharmaceuticals, Inc; Samsung Bioepis Co. Ltd; AffaMed Therapeutics; Amgen Inc; Novartis AG; CANbridge Pharmaceuticals, Inc.

Key players are adopting various strategies such as licensing agreement, collaboration and partnerships. For instance, Samsung Bioepis Co. Ltd. entered in China by licensing agreement with C-Bridge Capital.

Samsung Bioepis Co. Ltd. and AffaMed Therapeutics announced that the China National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for SB12, also referred to as AMT904 in China - a biosimilar candidate referencing Soliris (eculizumab). SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria.

Iptacopan- Pipeline drug of Novartis for paroxysmal nocturnal hemoglobinuria.

CANbridge is developing CAN106 in conjunction with WuXi Biologics for treatment of paroxysmal nocturnal hemoglobinuria.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139792/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics
Chapter 4: Presenting the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139792/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.